Trastuzumab Deruxtecan Package Insert

Enhertu 100 mg single-dose vial. Referenced with permission from the NCCN Drugs Biologics Compendium NCCN.

Https Www Accessdata Fda Gov Drugsatfda Docs Label 2019 761139s000lbl Pdf

Billing CodeAvailability Information HCPCS Code.

Trastuzumab deruxtecan package insert. Enhertu 100 mg single-dose vial. ENHERTU fam-trastuzumab deruxtecan-nxki and not trastuzumab or ado-trastuzumab emtansine. 1 billable unit 1 mg NDC.

Unprecedented efficacy in late line HER2 metastatic breast cancer Pertuzumab trastuzumab. Follow applicable special handling and disposal procedures. J9358 Injection fam-trastuzumab deruxtecan-nxki 1 mg.

Refer to the package insert for transitioning from trastuzumab andor pertuzumab intravenous. Breast cancer that cannot be removed by surgery or that has spread to other parts of your body metastatic and who have received two or more prior anti-HER2 breast cancer treatments. Fam-trastuzumab deruxtecan-nxki is compatible with an infusion bag made of polyvinylchloride or polyolefin copolymer of ethylene and polypropylene Administration 1.

Do not substitute PHESGO for or with pertuzumab trastuzumab ado-trastuzumab emtansine or fam-trastuzumab deruxtecan. Follow applicable special handling and disposal procedures. Refer to the package insert for timing and sequence of dosing with other chemotherapy.

1 billable unit 1 mg NDC. Reconstitute and further dilute ENHERTU prior to intravenous infusion. How does fam-trastuzumab deruxtecan-nxki Enhertu work.

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with. Unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the. J9358 Injection fam-trastuzumab deruxtecan-nxki 1 mg.

1 Daiichi Sankyos RD Day December 2018 2 T-DM1 FDA label and 3 Ogitani et al 2016 Cancer Science for DS-8201 Bystander Killing effect. This indication is approved under accelerated approval based on tumor. More than one vial may be needed for a full dose.

Enhertu fam-trastuzumab deruxtecan-nxki in the US only. ENHERTU fam-trastuzumab deruxtecan-nxki is a cytotoxic drug. Action Date Submission Supplement Categories or Approval Type Letters Reviews Labels Patient Package Insert Note Url.

Each vial delivers 100 mg of fam-trastuzumab deruxtecan-nxki L-histidine 445 mg L-histidine hydrochloride monohydrate 202 mg polysorbate 80 15 mg and sucrose 450 mg. Follow applicable special handling and disposal procedures1 Reconstitution Reconstitute immediately before dilution. PHESGO must always be administered by a healthcare professional.

IV over 30 90 minutes with an infusion set made of polyolefin or polybutadiene and a 02- or 022-micron in-line polyethersulfone or polysulfone filter. 12 The antibody is an IgG 1 kappa that contains human framework regions with the complementarity-determining regions of a. Calculate the dose mg the.

Enhertu 100 mg single-use vial. Use appropriate aseptic technique. Reconstitution Reconstitute immediately before dilution.

Enhertu targets a protein on the surface of breast cancer cells known as Human Epidermal growth factor Receptor 2 HER-2. ENHERTU fam-trastuzumab deruxtecan-nxki is a sterile white to yellowish white preservative-free lyophilized powder in single-dose vials. J9358 - Injection fam-trastuzumab deruxtecan-nxki 1 mg.

Once Enhertu binds to the breast cancer cell it enter the cell and releases a molecule called deruxtecan DXd a type of topoisomerase-I inhibitor designed to stop breast cancer cells from growing and dividing. ENHERTU fam-trastuzumab deruxtecan-nxki is a cytotoxic drug. Trastuzumab deruxtecan outside the US is the lead product in the ADC Franchise of the Daiichi Sankyo Cancer Enterprise and the most advanced programme in AstraZenecas ADC scientific platform.

ENHERTU is a prescription medicine used in adults to treat human epidermal growth factor receptor 2 HER2-positive. Pertuzumab intravenous trastuzumab and subcutaneous trastuzumab when administered alone. Intravenous trastuzumab and subcutaneous trastuzumab when administered alone.

1 billable unit 1 mg NDC. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy payload to cancer cells via a linker attached to a. DS-8201 trastuzumab deruxtecan Validated topo-1 mechanism Sources.

Calculate the dose mg the total volume of reconstituted. More than one vial may be needed for a full dose. Pronunciation of trastuzumab deruxtecan with 1 audio pronunciations 0 rating rating ratings Record the pronunciation of this word in your own.

ENHERTU fam-trastuzumab deruxtecan-nxki is a cytotoxic drug. HERCEPTIN Trastuzumab is a recombinant DNA-derived humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay Kd 5 nM to the extracellular domain of the human epidermal growth factor receptor 2 protein HER2.

Trastuzumab Deruxtecan Drug Description Adc Review

Enhertu For Healthcare Professionals

Https Www Modahealth Com Pdfs Med Criteria Enhertu Pdf

Enhertu Package Insert Public Health

Trastuzumab Deruxtecan Drug Description Adc Review

Targeting Her2 With Trastuzumab Deruxtecan A Dose Expansion Phase I Study In Multiple Advanced Solid Tumors Cancer Discovery

These Highlights Do Not Include All The Information Needed To Use Enhertu Safely And Effectively See Full Prescribing Information For Enhertu Enhertu Fam Trastuzumab Deruxtecan Nxki For Injection For Intravenous Use Initial U S Approval